Clinical trials: Single Coronary Vessel Disease
Coronary Artery Disease, Percutaneous Coronary Intervention
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
The APLABE-PCI is a single-center, randomized, open-label, controlled, dose-escalating, parallel-group study, which is designed to assess the anti-platelet effect of berberine in approximately 64 patients receiving aspirin and…
- Trial name
- APLABE-PCI (NCT03378934)
- Testing
- Berberine, Standard treatment, Aspirin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking Union Medical College Hospital
Coronary Stenosis
BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial
This is a prospective, multi-center, single-arm, open-label clinical trial. Clinical follow-up will be performed at 30 days. Follow-up by phone will be performed at 6 months, and 1 year after the procedure.
- Trial name
- NCT03702608
- Testing
- EluNIR Ridaforolimus Eluting Coronary Stent System
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Medinol Ltd.
Ischemic Heart Disease
Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve
In patients with 50-90% stenosis of the coronary artery, the coronary roadmap (dynamic roadmap) is performed when the conventional fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are performed.
- Trial name
- ROAD-IFR (NCT05682118)
- Testing
- roadmap, iFR/FFR
- Where
- South Korea
- Volunteers
- 226 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Percutaneous Coronary Intervention
Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention Strategies
The goal of this clinical trial is to find out whether a treatment strategy based on a drug-coated balloon (DCB) achieves coronary artery function at 6 months that is not worse than a strategy using only drug-eluting stents (DES)…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Drug Coated Balloon, Drug Eluting Stents (DES)
- Trial name
- FLOW-DCB (NCT07852689)
- Testing
- Drug-coated balloon-based intervention, Drug-eluting stent-based intervention
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Korea University Guro Hospital
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Hypertension and Chronic Heart Failure
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
The purpose of this study is to to assess the safety and tolerability of BIA 5 1058 after single and multiple oral doses
- Trial name
- NCT02151994
- Testing
- BIA 5-1058
- Where
- Netherlands
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Coronary Artery Occlusive Disease (CAOD)
The Characteristics and Treatment Mechanism of Vascular Grafts in Elderly Patients With CAOD Through Single-cell Transcriptome Analysis
This study aims to establish a cardiovascular biobank using vascular grafts obtained from participants with coronary artery occlusive disease (CAOD).
- Trial name
- NCT07053254
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS).
- Trial name
- NCT02514642
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Heart Failure, Cardiogenic Shock
Oxygen Delivery Index (ODIN) Study
The objective of this study is to test the feasibility and efficacy of a novel, non-invasive electronic device to monitor the adequacy of tissue perfusion in patients with advanced heart failure or cardiogenic shock in the ICU.
- Trial name
- NCT07601828
- Testing
- Oxygen Delivery Index (ODIN) Device
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Coronary Artery Disease
EVOLVE Short DAPT Study
The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
- Trial name
- NCT02605447
- Testing
- 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
- Where
- 110 sites in United States, Brazil and 5 more
- Volunteers
- 2,009 people
- Sponsor
- Boston Scientific Corporation
Single Coronary Vessel Disease
A First-in-Man Study of IBS
The study is a pilot clinical trial for Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System（IBS）. The main purpose of this study is to evaluate the feasibility, preliminary safety and efficacy of IBS.
- Trial name
- IBS-FIM (NCT03509142)
- Testing
- Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Coronary Artery Disease
Study of the Orsiro Drug Eluting Stent System
The purpose of this study is to compare the BIOTRONIK Orsiro Drug Eluting Stent System with the Abbott Xience Prime™ Drug Eluting Stent System with respect to in-stent Late Lumen Loss in a non-inferiority study in de novo…
- Trial name
- BIOFLOW-II (NCT01356888)
- Testing
- Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES), Percutaneous Coronary Intervention (Orsiro DES)
- Where
- 24 sites in Austria, France and 6 more
- Volunteers
- 452 people
- Sponsor
- Biotronik AG
Myocardial Infarction
Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)
Rationale: ST-elevation myocardial infarction (STEMI) is usually triggered by rupture of an atherosclerotic plaque that then accumulates platelets and fibrin and leads to an occlusive coronary thrombus.
- Trial name
- NCT00251823
- Testing
- Eptifibatide facilitated PCI
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Aortic Stenosis Treated With TAVI, Aortic Diseases
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
The objective of this pivotal study is to compare the safety and effectiveness of the F2 CPC (Treatment group) to a Control group (no embolic protection) in participants undergoing transfemoral (TF) TAVR with commercially…
- Trial name
- SHIELD (NCT06689839)
- Testing
- F2 Filter and Delivery System, Transcatheter Aortic Valve Replacement (TAVR)
- Where
- 10 sites in United States, Australia
- Volunteers
- 500 people
- Sponsor
- EnCompass Technologies, Inc.
Coronary Artery Disease, Postoperative Complications
Intraoperative Targeted Versus Liberal Blood Pressure Management in Patients Undergoing Off-pump Coronary Artery Bypass Grafting
The goal of this clinical trial is to learn whether two approaches to anesthesia and blood pressure management can improve care for adults having off-pump coronary artery bypass grafting (OPCAB).
- Trial name
- NCT07787364
- Testing
- Targeted Blood Pressure Management, Liberal Blood Pressure Management, Remimazolam
- Volunteers
- 416 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Aortic Valve Stenosis, Structural Valve Deterioration
Single Perclose Escalation Technique for Vascular Closure in TAVR
This study examines in the safety and efficacy of using a single Perclose escalation technique (SPET) using a single Perclose Proglide device to preclose and the need for a rescue device based on a control angiography at the end…
- Conditions
- Aortic Valve Stenosis, Structural Valve Deterioration, Structural Valve Degeneration
- Trial name
- NCT05836311
- Testing
- One Perclose Proglide Suture, Two Perclose Proglide Suture
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Class IV Angina
Cardiogenesis Transmyocardial Revascularization Registry
The objectives of the registry are as follows: Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System; Further define the disease characteristics of the population being treated…
- Trial name
- ANGINA RELIEF (NCT01827319)
- Where
- 24 sites in United States
- Volunteers
- 203 people
- Sponsor
- Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
ST-segment Elevation Myocardial Infarction
Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before Percutaneous Coronary Intervention (PCI) in Patients with ST-segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT02770664
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- LG Life Sciences
Coronary Microcirculation, Coronary Artery Disease
Impact of Ranolazine on Coronary Microcirculatory Resistance
This study is being done to determine if Ranolazine treatment improves coronary microcirculation function among patients with coronary microcirculation dysfunction.
- Conditions
- Coronary Microcirculation, Coronary Artery Disease, Myocardial Disease, Ischemia
- Trial name
- NCT01815957
- Testing
- Rnalozine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of New Mexico
Coronary Artery Disease, Anesthesia
Influence of Oxygen on Perioperative Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery
The purpose of this study is to investigate the impact of supraphysiologic oxygen (hyperoxia) on myocardial function in anaesthetized patients undergoing non-cardiac vascular surgery.
- Trial name
- Promise-O2 (NCT04808401)
- Testing
- Oxygen
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern